Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure (INFUSE-AHF)

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523589-26-00

Enrollment

436

Registered

2026-04-24

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute heart failure with volume overload

Brief summary

Net weight loss 3 days (≈72 hours) after randomisation

Detailed description

Net weight loss 2 days (≈48 hours) after randomisation, Change in dyspnea on a Visual Analogue Scale 3 days (≈72 hours) after randomisation, Days alive out-of-hospital to Day 30, Length of stay

Interventions

DRUGFUROSEMIDE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Net weight loss 3 days (≈72 hours) after randomisation	—

Secondary

Measure	Time frame
Net weight loss 2 days (≈48 hours) after randomisation, Change in dyspnea on a Visual Analogue Scale 3 days (≈72 hours) after randomisation, Days alive out-of-hospital to Day 30, Length of stay	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 25, 2026